Parkinson Disease, IdiopathicEarly Phase 1NCT06954662
A Targeted Amino Acid Supplement for People With Parkinson's Disease
A Early Phase 1 study testing Amino acid supplement and Whey Protein Supplement in people with Parkinson Disease, Idiopathic, run by UConn Health at 1 site in United States.
Trial summary
The goal of this clinical trial is to learn if an amino acid supplement that is specifically made for people with Parkinson disease can improve nutrition without interfering with dopamine medication in people living with Parkinson disease. Read more about this study
- Who is it for?
- Ages 55 years and older
- Conditions the study is for
- Parkinson Disease, Idiopathic
- What is being tested?
- Amino acid supplement and Whey Protein Supplement
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 3 participants
- Where
- 1 siteUnited States
- Study dates
- 22 May 2025to 17 Jul 2025
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- diagnosis of idiopathic Parkinson disease by patient report
- 55 years or older
- Has been using dopamine replacement medication (e.g. levodopa) for at least 2 years.
- On a stable dose of dopamine replacement medication for at least 3 months with no plans for change in the next two months.
Who cannot join
- Apparent cognitive impairment as determined by phone screening (TICS)
- Diagnosis of Parkinsonism or atypical Parkinson's Disease
- Are prescribed a dopamine antagonist
- Any unstable medical condition
- Any known bleeding disorder or currently taking blood thinners
- Using deep brain stimulation
- Gastric or bowel resection surgery
Trial locations and contacts
1 site in 1 country.
United States1 site
UConn Health, Clinical Research Center
Farmington, Connecticut, 06030-3805
About this study
Official title: Comparison of Whey Protein and Amino Acid Supplementation on Amino Acid and Levodopa Concentrations in People With Parkinson's Disease
The goal of this clinical trial is to learn if an amino acid supplement that is specifically made for people with Parkinson disease can improve nutrition without interfering with dopamine medication in people living with Parkinson disease. The main question it aims to answer is:
- Does an amino acid supplement that is specifically made for people with Parkinson disease have short-term improvements in nutrition deficiencies, while minimally interfering with Parkinson disease medication?
Read more
Researchers will compare the short-term effects of this specialized nutrition supplement to a supplement that is available for everyone to purchase in a store (whey protein supplement-a milk by-product) and to an inactive supplement. Researchers will then check for the indicators of nutrition levels and the presence of dopamine medication in the blood. Researchers will also assess mood and movement abilities in participants.
Participants will be asked to:
- attend 4 study visits over the course of 4 weeks (initial orientation visit plus 3 intervention visits).
- drink one of the 3 supplements (supplements will be mixed into water to create a beverage) at each of the 3 intervention visits.
- participate in blood drawings and mood and movement assessments at each of the intervention visits.
- engage in a phone call after each intervention visit to determine any delayed responses.
Read the detailed description
This is a prospective, double-blind, randomized control trial with a repeated measures design. After being screened via phone screens and completing an initial visit that includes additional in person screening and the collection of descriptive information, participants will be invited to take part in three experimental sessions. On three separate days participants with idiopathic Parkinson's Disease and taking a stable dose of dopamine replacement medication, 2-3 hours after a standardized low-protein meal, will orally take a habitual dose of L-Dopa medication and then engage in one of the three interventions 1) WP-S: whey protein supplement (20 g), 2) AA-S: targeted amino acid supplement (equivalent amino acid load to whey protein beverage) 3) CON-S: an isonitrogenous placebo beverage (equivalent amino acid load to whey protein beverage), prescribed in a randomized and counterbalanced manner. Prior to, and up to 3 hours after medication, blood samples will be collected every 15 min for 90 min and every 30 min thereafter and then analyzed to determine circulating L-dopa and amino acid profiles using high-performance liquid chromatography. During this observation period changes in both motor (Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part 3 (MDSUPDRS III), finger tapping, and Timed Up and Go Test) and non-motor disease symptoms (Profile of Mood State with component analysis of depression, fatigue, and anxiety) will be measured every 30 minutes.
All supplements will be provided for the study in coded prepackaged envelopes by an independent nutritional supplement company based on the formulas provided below, to ensure double blinding.
Whey Protein Supplement (WP-S): Whey protein is one of the primary proteins found in all dairy products. It is a complete protein as it contains all the essential amino acids. A previous investigation has been performed looking at the long -term (6 months) effects of whey protein supplementation on health and disease symptoms of people with Parkinson's Disease. This study validated the safety and efficacy of whey protein supplementation in people with Parkinson's Disease, but a non-significant increase in disease symptoms (during medication off time) was reported. Similar to this previous study, we will use a standard 20 g dose of whey protein.
Targeted Amino Acid Supplement (AA-S): Previous studies have investigated the long-term (6 months) effects of amino acid supplementation on health and disease symptoms of people with Parkinson's Disease. The previous whey protein study, and the previous amino acid supplement study, validated the safety and efficacy of an amino acid supplement in people with Parkinson's Disease but a non-significant increase in disease symptoms (during medication off time) was reported. However, the supplement in these studies was not designed to minimize the components which could interfere with levodopa medication.
In contrast, the AA-S used in the present study was designed off the amino acid composition of WP-S, but then was modified to minimize interference with levodopa by reducing the quantity of amino acids which are known to interfere with levodopa (large neutral amino acids), which collectively resulted in a 59% reduction in competing amino acids. Additionally, the concentrations of other non-competing amino acids were modified in order to fill the previously identified nutritional deficiency observed in people with PD.
Isonitrogenous Placebo Supplement (CON-S): The control supplement used in this study is an isonitrogenous placebo beverage. This supplement will consist of an inert amino acid (alanine) with the same amino acid load as the WP-S and AA-S (16.2 g).
- Conditions
- Parkinson Disease, Idiopathic
- Being tested
- Amino acid supplement, Whey Protein Supplement, Isonitrogenous Placebo Supplement
- Keywords
- Nutrition, Amino acid supplementation, Parkinson disease
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Amino acid supplementDrug
Also called AA-S
a targeted amino acid supplement designed to provide dietary nutrients that are commonly deficient in people with PD while minimizing interference with L-Dopa medication
Whey Protein SupplementDietary supplement
Also called WP-S
Whey protein is one of the primary proteins found in all dairy products. It is a complete protein as it contains all the essential amino acids. We will use a 20 gram dose.
Isonitrogenous Placebo SupplementDietary supplement
Also called CON-S
The control supplement used in this study is an isonitrogenous placebo beverage. This supplement will consist of an inert amino acid (alanine) with the same amino acid load as the whey protein and the targeted amino acid supplement (16.2 grams).
| Study group | Role | What they receive |
|---|---|---|
| Whey Protein Supplement (WP-S) | Active comparator | Whey protein is one of the primary proteins found in all dairy products. It is a complete protein as it contains all the essential amino acids. It is commercially available as a dietary supplement (a standard 20 g dose of whey). Receives: Dietary Supplement: Whey Protein Supplement |
| Isonitrogenous Placebo Supplement (CON-S) | Placebo comparator | The control supplement used in this study is an isonitrogenous placebo beverage. This supplement will consist of an inert amino acid (alanine) with the same amino acid load as the WP-S and AA-S (16.2 g). Receives: Dietary Supplement: Isonitrogenous Placebo Supplement |
| Amino acid supplement (AA-S) | Experimental | designed off the amino acid composition of the why protein supplement, but then was modified to minimize interference with levodopa by reducing the quantity of amino acids which are known to interfere with levodopa, which collectively resulted in a 59% reduction in competing amino acids. Additionally, the concentrations of other non-competing amino acids were modified in order to fill the previously identified nutritional deficiency observed in people with PD. Receives: Drug: Amino acid supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Circulating levodopa
Circulating levodopa will be measured from the 10 blood samples at each of the three study visits.
Measured: study session 2 (Week 2), 3 (Week 3), and 4 (Week 4). Each session will last approximately 3-4 hours.
Circulating amino acids concentrations
High performance liquid chromatography will be used to assess amino acid concentrations in blood samples (10) from each intervention session
Measured: Session 2 (Week 2), Session 3 (Week 3), Session 4 (Week 4)
Secondary outcomes (4)
Unified Parkinson Disease Rating Scale, Part III
Disease motor symptoms will be assessed via Part 3 of the UPDRS. Research staff that have completed training to administer and grade this test by the International Parkinson and Movement Disorder Society will complete this assessment. This portion of the UPDRS is designed to test motor symptoms related to Parkinson's Disease. The test includes quick clinical assessments of passive rigidity, finger and toe tapping, hand and forearm movement, chair standing, gait (10 meter) assessment, and postural assessment.
Measured: This test will be performed prior to medication (Pre/+0 minutes) and at the end of testing (+180 minutes) at each of the 3 intervention sessions (Session 2/Week 2, Session 3/Week 3, Session 4/Week 4)
Timed Up and Go Test
The timed up and go test will be performed as an additional physical symptom assessment. In this test the participant will start in a seated position, then stand up, walk 3 meters and then turn around and return to the chair.
Measured: This test will be performed every 30 minutes (+0, +30, +60, +90, +120, +150, and +180 minutes) at each of the intervention sessions (Session 2/Week 2, Session 3/Week 3, Session 4/Week 4).
Abbreviated Profile of Mood State
Abbreviated Profile of Mood States (POMS) Questionnaire: This an assessment of current mood state. It is a 40-item self-report survey that evaluates the degree to which a participant is feeling a selected emotion at the moment.
Measured: This test will be performed prior to medication (Pre/+0 minutes) and at the end of testing (+180 minutes) at each intervention session.
30 second Finger Tapping
The 30 second finger tapping test is an assessment of fine motor control. The participant will sit upright in a chair with their most affected (with the greatest disease symptoms) hand positioned over a tablet. In this position the participant will tap the screen as many times as they can for 30 seconds, and the total number of taps will be recorded.
Measured: This test will be performed every 30 minutes (+0, +30, +60, +90, +120, +150, and +180 minutes) at each intervention session
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 May 2025
- Study start22 May 2025
- Primary completion17 Jul 2025
- Study completion17 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Parkinson Disease, IdiopathicStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- This is a prospective, double-blind, randomized control trial with a repeated measures design in a single group.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 3 participants (actual)
Sponsor and investigators
- Lead sponsor
- UConn Health
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Cristina Colón-Semenza, UConn Health
- Investigators
- Cristina Colon-Semenza, PT, MPT, PhD, Principal investigator, University of ConnecticutJacob Earp, PhD, Principal investigator, University of Connecticut
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06954662
- Sponsor's protocol ID
- 24-017S-1
- Status last verified
- Aug 2026
- First submitted
- 28 Mar 2025
- Last updated
- 13 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: The funding for reviewing requests, storing and managing data, and sharing IPD is undetermined at this time.
Publications
Earp JE, Colon-Semenza C, LoBuono DL. Considerations for developing a targeted amino acid supplement for people with Parkinson's disease that promotes health while accounting for pathophysiology and medication interference. Nutr Rev. 2023 Jul 10;81(8):1063-1076. doi: 10.1093/nutrit/nuad008.
PubMed 36809398
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Whey Protein and Amino Acid Supplementation on Amino Acid and Levodopa Concentrations in People With Parkinson's Disease
- ClinicalTrials.gov ID
- NCT06954662
- Acronym / sponsor ID
- 24-017S-1
- Conditions
- Parkinson Disease, Idiopathic
- Keywords
- Nutrition, Amino acid supplementation, Parkinson disease
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 3 participants (actual)
- Lead sponsor
- UConn HealthUniversity, hospital or other
- Study start
- 22 May 2025 (actual)
- Primary completion
- 17 Jul 2025 (actual)
- Study completion
- 17 Jul 2025 (actual)
- First posted
- 1 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if an amino acid supplement that is specifically made for people with Parkinson disease can improve nutrition without interfering with dopamine medication in people living with Parkinson disease. The main question it aims to answer is:
- Does an amino acid supplement that is specifically made for people with Parkinson disease have short-term improvements in nutrition deficiencies, while minimally interfering with Parkinson disease medication?
Researchers will compare the short-term effects of this specialized nutrition supplement to a supplement that is available for everyone to purchase in a store (whey protein supplement-a milk by-product) and to an inactive supplement. Researchers will then check for the indicators of nutrition levels and the presence of dopamine medication in the blood. Researchers will also assess mood and movement abilities in participants.
Participants will be asked to:
- attend 4 study visits over the course of 4 weeks (initial orientation visit plus 3 intervention visits).
- drink one of the 3 supplements (supplements will be mixed into water to create a beverage) at each of the 3 intervention visits.
- participate in blood drawings and mood and movement assessments at each of the intervention visits.
- engage in a phone call after each intervention visit to determine any delayed responses.
Detailed description
This is a prospective, double-blind, randomized control trial with a repeated measures design. After being screened via phone screens and completing an initial visit that includes additional in person screening and the collection of descriptive information, participants will be invited to take part in three experimental sessions. On three separate days participants with idiopathic Parkinson's Disease and taking a stable dose of dopamine replacement medication, 2-3 hours after a standardized low-protein meal, will orally take a habitual dose of L-Dopa medication and then engage in one of the three interventions 1) WP-S: whey protein supplement (20 g), 2) AA-S: targeted amino acid supplement (equivalent amino acid load to whey protein beverage) 3) CON-S: an isonitrogenous placebo beverage (equivalent amino acid load to whey protein beverage), prescribed in a randomized and counterbalanced manner. Prior to, and up to 3 hours after medication, blood samples will be collected every 15 min for 90 min and every 30 min thereafter and then analyzed to determine circulating L-dopa and amino acid profiles using high-performance liquid chromatography. During this observation period changes in both motor (Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part 3 (MDSUPDRS III), finger tapping, and Timed Up and Go Test) and non-motor disease symptoms (Profile of Mood State with component analysis of depression, fatigue, and anxiety) will be measured every 30 minutes.
All supplements will be provided for the study in coded prepackaged envelopes by an independent nutritional supplement company based on the formulas provided below, to ensure double blinding.
Whey Protein Supplement (WP-S): Whey protein is one of the primary proteins found in all dairy products. It is a complete protein as it contains all the essential amino acids. A previous investigation has been performed looking at the long -term (6 months) effects of whey protein supplementation on health and disease symptoms of people with Parkinson's Disease. This study validated the safety and efficacy of whey protein supplementation in people with Parkinson's Disease, but a non-significant increase in disease symptoms (during medication off time) was reported. Similar to this previous study, we will use a standard 20 g dose of whey protein.
Targeted Amino Acid Supplement (AA-S): Previous studies have investigated the long-term (6 months) effects of amino acid supplementation on health and disease symptoms of people with Parkinson's Disease. The previous whey protein study, and the previous amino acid supplement study, validated the safety and efficacy of an amino acid supplement in people with Parkinson's Disease but a non-significant increase in disease symptoms (during medication off time) was reported. However, the supplement in these studies was not designed to minimize the components which could interfere with levodopa medication.
In contrast, the AA-S used in the present study was designed off the amino acid composition of WP-S, but then was modified to minimize interference with levodopa by reducing the quantity of amino acids which are known to interfere with levodopa (large neutral amino acids), which collectively resulted in a 59% reduction in competing amino acids. Additionally, the concentrations of other non-competing amino acids were modified in order to fill the previously identified nutritional deficiency observed in people with PD.
Isonitrogenous Placebo Supplement (CON-S): The control supplement used in this study is an isonitrogenous placebo beverage. This supplement will consist of an inert amino acid (alanine) with the same amino acid load as the WP-S and AA-S (16.2 g).
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- This is a prospective, double-blind, randomized control trial with a repeated measures design in a single group.
| Arm | Type | Receives |
|---|---|---|
| Whey Protein Supplement (WP-S) | Active comparator | Dietary Supplement: Whey Protein SupplementWhey protein is one of the primary proteins found in all dairy products. It is a complete protein as it contains all the essential amino acids. It is commercially available as a dietary supplement (a standard 20 g dose of whey). |
| Isonitrogenous Placebo Supplement (CON-S) | Placebo comparator | Dietary Supplement: Isonitrogenous Placebo SupplementThe control supplement used in this study is an isonitrogenous placebo beverage. This supplement will consist of an inert amino acid (alanine) with the same amino acid load as the WP-S and AA-S (16.2 g). |
| Amino acid supplement (AA-S) | Experimental | Drug: Amino acid supplementdesigned off the amino acid composition of the why protein supplement, but then was modified to minimize interference with levodopa by reducing the quantity of amino acids which are known to interfere with levodopa, which collectively resulted in a 59% reduction in competing amino acids. Additionally, the concentrations of other non-competing amino acids were modified in order to fill the previously identified nutritional deficiency observed in people with PD. |
Who may qualify
- Ages
- 55 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- diagnosis of idiopathic Parkinson disease by patient report
- 55 years or older
- Has been using dopamine replacement medication (e.g. levodopa) for at least 2 years.
- On a stable dose of dopamine replacement medication for at least 3 months with no plans for change in the next two months.
Key exclusion criteria (7 listed)
- Apparent cognitive impairment as determined by phone screening (TICS)
- Diagnosis of Parkinsonism or atypical Parkinson's Disease
- Are prescribed a dopamine antagonist
- Any unstable medical condition
- Any known bleeding disorder or currently taking blood thinners
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Amino acid supplementAlso: AA-Sa targeted amino acid supplement designed to provide dietary nutrients that are commonly deficient in people with PD while minimizing interference with L-Dopa medication | Drug | Amino acid supplement (AA-S) |
| Whey Protein SupplementAlso: WP-SWhey protein is one of the primary proteins found in all dairy products. It is a complete protein as it contains all the essential amino acids. We will use a 20 gram dose. | Dietary supplement | Whey Protein Supplement (WP-S) |
| Isonitrogenous Placebo SupplementAlso: CON-SThe control supplement used in this study is an isonitrogenous placebo beverage. This supplement will consist of an inert amino acid (alanine) with the same amino acid load as the whey protein and the targeted amino acid supplement (16.2 grams). | Dietary supplement | Isonitrogenous Placebo Supplement (CON-S) |
Primary outcome
Circulating levodopa
Time frame: study session 2 (Week 2), 3 (Week 3), and 4 (Week 4). Each session will last approximately 3-4 hours.
Circulating levodopa will be measured from the 10 blood samples at each of the three study visits.
Circulating amino acids concentrations
Time frame: Session 2 (Week 2), Session 3 (Week 3), Session 4 (Week 4)
High performance liquid chromatography will be used to assess amino acid concentrations in blood samples (10) from each intervention session
4 secondary outcomes
Unified Parkinson Disease Rating Scale, Part III
Time frame: This test will be performed prior to medication (Pre/+0 minutes) and at the end of testing (+180 minutes) at each of the 3 intervention sessions (Session 2/Week 2, Session 3/Week 3, Session 4/Week 4)
Timed Up and Go Test
Time frame: This test will be performed every 30 minutes (+0, +30, +60, +90, +120, +150, and +180 minutes) at each of the intervention sessions (Session 2/Week 2, Session 3/Week 3, Session 4/Week 4).
Abbreviated Profile of Mood State
Time frame: This test will be performed prior to medication (Pre/+0 minutes) and at the end of testing (+180 minutes) at each intervention session.
30 second Finger Tapping
Time frame: This test will be performed every 30 minutes (+0, +30, +60, +90, +120, +150, and +180 minutes) at each intervention session
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2026.
- Background: PubMed 36809398Earp JE, Colon-Semenza C, LoBuono DL. Considerations for developing a targeted amino acid supplement for people with Parkinson's disease that promotes health while accounting for pathophysiology and medication interference. Nutr Rev. 2023 Jul 10;81(8):1063-1076. doi: 10.1093/nutrit/nuad008.
- Individual participant dataSharing planned: No. The funding for reviewing requests, storing and managing data, and sharing IPD is undetermined at this time.
Related trials for Parkinson Disease, Idiopathic
Not yet recruitingObservational study
Longitudinal Observation of Neurodegeneration in Parkinson's Disease Using Molecular Imaging and Blood Biomarkers
Idiopathic Parkinson Disease
Not yet recruiting
Non-invasive Vagus Nerve Stimulation for Parkinson's Disease
Idiopathic Parkinson Disease
RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Parkinson Disease, Parkinson
Recruiting
MediPD: An Online Mediterranean Diet Program for People Living With Parkinson's Disease
Parkinson Disease, Idiopathic
Recruiting
Ginger-PD: Ginger as a Modifier of Ghrelin Levels and Gut Function in Parkinson's Disease
REM Sleep Behavior Disorder, Parkinson s Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Cristina Colon-Semenza, PT, MPT, PhD principal investigator
University of Connecticut
Jacob Earp, PhD principal investigator
University of Connecticut
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Amino acid supplement and Whey Protein Supplement in people with Parkinson Disease, Idiopathic, run by UConn Health at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Circulating levodopa (time frame: study session 2 (Week 2), 3 (Week 3), and 4 (Week 4). Each session will last approximately 3-4 hours.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06954662, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026.